Literature DB >> 30467046

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

Maarten Niemantsverdriet1, Ed Schuuring1, Arja Ter Elst1, Antonie J van der Wekken2, Leon C van Kempen1, Anke van den Berg1, Harry J M Groen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30467046     DOI： 10.1016/j.jtho.2018.07.103

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

Review 1.  BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.

Authors:  Ioannis Tsamis; Georgia Gomatou; Stavroula Porfyria Chachali; Ioannis Panagiotis Trontzas; Vasileios Patriarcheas; Emmanouil Panagiotou; Elias Kotteas
Journal:  Clin Transl Oncol       Date:  2022-06-21       Impact factor: 3.405

Review 2.  BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.

Authors:  Ningning Yan; Sanxing Guo; Huixian Zhang; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

Review 3.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

4.  Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.

Authors:  Jingjing Qu; Qian Shen; Yuping Li; Farhin Shaheed Kalyani; Li Liu; Jianya Zhou; Jianying Zhou
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

5.  [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-09-20

Review 6.  [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer].

Authors:  Na Li; Yanjun Xu; Yun Fan
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-10-20

7.  Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment.

Authors:  Ruihan Luo; Chuang Ge; Xiao Xiao; Jing Song; Shiqi Miao; Yongyao Tang; Jiayi Lai; Weiqi Nian; Fangzhou Song; Longke Ran
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

8.  Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples.

Authors:  Saskia Offerman; Clemens F Prinsen; Ageeth Knol; Natalie Methorst; Jeanette Kamphorst; Maarten Niemantsverdriet
Journal:  Diagn Pathol       Date:  2021-08-03       Impact factor: 2.644
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.